메뉴 건너뛰기




Volumn 35, Issue s1, 2015, Pages 35-43

Optimal management of patients with chronic hepatitis C and comorbidities

Author keywords

Cost effectiveness; Direct acting antivirals; Hepatitis C virus; Modifiable; Non modifiable comorbidities; Sustained viral response

Indexed keywords

ANTIVIRAL AGENTS; PROTEASE INHIBITORS;

EID: 84919686293     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12712     Document Type: Review
Times cited : (12)

References (76)
  • 1
    • 33947360829 scopus 로고    scopus 로고
    • Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study
    • Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87.
    • (2007) Hepatology , vol.45 , pp. 579-587
    • Bruno, S.1    Stroffolini, T.2    Colombo, M.3
  • 2
    • 84871487025 scopus 로고    scopus 로고
    • Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
    • Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.
    • (2012) JAMA , vol.308 , pp. 2584-2593
    • Van der Meer, A.J.1    Veldt, B.J.2    Feld, J.J.3
  • 3
    • 0032922191 scopus 로고    scopus 로고
    • Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients
    • Neary MP, Cort S, Bayliss MS, et al. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999; 19(Suppl. 1): 77-85.
    • (1999) Semin Liver Dis , vol.19 , pp. 77-85
    • Neary, M.P.1    Cort, S.2    Bayliss, M.S.3
  • 4
    • 33644509858 scopus 로고    scopus 로고
    • Hepatitis C - identifying patients with progressive liver injury
    • Feld JJ, Liang TJ. Hepatitis C - identifying patients with progressive liver injury. Hepatology 2006; 43(2 Suppl. 1): S194-206.
    • (2006) Hepatology , vol.43 , Issue.2 , pp. S194-S206
    • Feld, J.J.1    Liang, T.J.2
  • 5
    • 0037219481 scopus 로고    scopus 로고
    • Progression of fibrosis in chronic hepatitis C
    • Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.
    • (2003) Gastroenterology , vol.124 , pp. 97-104
    • Ghany, M.G.1    Kleiner, D.E.2    Alter, H.3
  • 6
    • 0035009810 scopus 로고    scopus 로고
    • Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c
    • Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 2001; 34: 730-9.
    • (2001) J Hepatol , vol.34 , pp. 730-739
    • Poynard, T.1    Ratziu, V.2    Charlotte, F.3
  • 7
    • 84907905914 scopus 로고    scopus 로고
    • Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring - predictors and predictive models of disease progression
    • Konerman MA, Yapali S, Lok AS. Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring - predictors and predictive models of disease progression. Aliment Pharmacol Ther 2014; 40: 863-79.
    • (2014) Aliment Pharmacol Ther , vol.40 , pp. 863-879
    • Konerman, M.A.1    Yapali, S.2    Lok, A.S.3
  • 8
    • 10744223184 scopus 로고    scopus 로고
    • Long-term outcome of hepatitis C infection after bone marrow transplantation
    • Peffault dLR, Lévy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004; 103: 1618-24.
    • (2004) Blood , vol.103 , pp. 1618-1624
    • Peffault, dLR.1    Lévy, V.2    Asselah, T.3
  • 9
    • 84907043631 scopus 로고    scopus 로고
    • Treating hepatitis C in the elderly: the future is near?
    • Conti F, Vitale G, Andreone P. Treating hepatitis C in the elderly: the future is near? Expert Opin Pharmacother 2014; 15: 2019-28.
    • (2014) Expert Opin Pharmacother , vol.15 , pp. 2019-2028
    • Conti, F.1    Vitale, G.2    Andreone, P.3
  • 10
    • 2442683905 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3
    • Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-9.
    • (2004) J Hepatol , vol.40 , pp. 993-999
    • Zeuzem, S.1    Hultcrantz, R.2    Bourliere, M.3
  • 11
    • 34250866397 scopus 로고    scopus 로고
    • The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr
    • Antonucci G, Longo MA, Angeletti C, et al. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol 2007; 102: 1383-91.
    • (2007) Am J Gastroenterol , vol.102 , pp. 1383-1391
    • Antonucci, G.1    Longo, M.A.2    Angeletti, C.3
  • 12
    • 77950599137 scopus 로고    scopus 로고
    • Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C
    • Honda T, Katano Y, Shimizu J, et al. Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver Int 2010; 30: 527-37.
    • (2010) Liver Int , vol.30 , pp. 527-537
    • Honda, T.1    Katano, Y.2    Shimizu, J.3
  • 13
    • 76449118685 scopus 로고    scopus 로고
    • Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C
    • Huang CF, Yang JF, Dai CY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010; 201: 751-9.
    • (2010) J Infect Dis , vol.201 , pp. 751-759
    • Huang, C.F.1    Yang, J.F.2    Dai, C.Y.3
  • 14
    • 77957585975 scopus 로고    scopus 로고
    • Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
    • Kainuma M, Furusyo N, Kajiwara E, et al. Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 2010; 16: 4400-9.
    • (2010) World J Gastroenterol , vol.16 , pp. 4400-4409
    • Kainuma, M.1    Furusyo, N.2    Kajiwara, E.3
  • 15
    • 84923204718 scopus 로고    scopus 로고
    • The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1
    • [Epub ahead of print]
    • Oze T, Hiramatsu N, Yakushijin T, et al. The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1. J Viral Hepat 2014; doi: 10.1111/jvh.12289. [Epub ahead of print]
    • (2014) J Viral Hepat
    • Oze, T.1    Hiramatsu, N.2    Yakushijin, T.3
  • 16
    • 84857935545 scopus 로고    scopus 로고
    • The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients
    • Nishikawa H, Iguchi E, Koshikawa Y, et al. The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients. BMC Res Notes 2012; 10: 135.
    • (2012) BMC Res Notes , vol.10 , pp. 135
    • Nishikawa, H.1    Iguchi, E.2    Koshikawa, Y.3
  • 17
    • 84864184655 scopus 로고    scopus 로고
    • Treatment response and tolerability of pegylated interferon-α plus ribavirin combination therapy in elderly patients (≥65 years) with chronic hepatitis C in Korea
    • Kim HI, Kim IH, Jeon BJ, et al. Treatment response and tolerability of pegylated interferon-α plus ribavirin combination therapy in elderly patients (≥65 years) with chronic hepatitis C in Korea. Hepat Mon 2012; 12: 430-6.
    • (2012) Hepat Mon , vol.12 , pp. 430-436
    • Kim, H.I.1    Kim, I.H.2    Jeon, B.J.3
  • 18
    • 84859873445 scopus 로고    scopus 로고
    • Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C
    • Yu JW, Sun LJ, Kang P, et al. Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C. Hepatobiliary Pancreat Dis Int 2012; 11: 185-92.
    • (2012) Hepatobiliary Pancreat Dis Int , vol.11 , pp. 185-192
    • Yu, J.W.1    Sun, L.J.2    Kang, P.3
  • 19
    • 84870601065 scopus 로고    scopus 로고
    • Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C
    • Hu CC, Lin CL, Kuo YL, et al. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Aliment Pharmacol Ther 2013; 37: 81-90.
    • (2013) Aliment Pharmacol Ther , vol.37 , pp. 81-90
    • Hu, C.C.1    Lin, C.L.2    Kuo, Y.L.3
  • 20
    • 84890868950 scopus 로고    scopus 로고
    • Management of HCV patients with cirrhosis with direct acting antivirals
    • Boccaccio V, Bruno S. Management of HCV patients with cirrhosis with direct acting antivirals. Liver Int 2014; 34(Suppl. 1): 38-45.
    • (2014) Liver Int , vol.34 , pp. 38-45
    • Boccaccio, V.1    Bruno, S.2
  • 21
    • 79959438789 scopus 로고    scopus 로고
    • Telaprevir for previously untreated chronic hepatitis C virus infection
    • Jacobson IM, McHutchinson JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
    • (2011) N Engl J Med , vol.364 , pp. 2405-2416
    • Jacobson, I.M.1    McHutchinson, J.G.2    Dusheiko, G.3
  • 22
    • 79959381354 scopus 로고    scopus 로고
    • Telaprevir for retreatment of HCV infection
    • Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
    • (2011) N Engl J Med , vol.364 , pp. 2417-2428
    • Zeuzem, S.1    Andreone, P.2    Pol, S.3
  • 23
    • 80052826527 scopus 로고    scopus 로고
    • Response-guided telaprevir combination treatment for hepatitis C virus infection
    • Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
    • (2011) N Engl J Med , vol.365 , pp. 1014-1024
    • Sherman, K.E.1    Flamm, S.L.2    Afdhal, N.H.3
  • 24
    • 77956268467 scopus 로고    scopus 로고
    • Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    • Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-16.
    • (2010) Lancet , vol.376 , pp. 705-716
    • Kwo, P.Y.1    Lawitz, E.J.2    McCone, J.3
  • 25
    • 79953173221 scopus 로고    scopus 로고
    • Boceprevir for untreated chronic HCV genotype 1 infection
    • Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
    • (2011) N Engl J Med , vol.364 , pp. 1195-1206
    • Poordad, F.1    McCone Jr, J.2    Bacon, B.R.3
  • 26
    • 79953176289 scopus 로고    scopus 로고
    • Boceprevir for previously treated chronic HCV genotype 1 infection
    • Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
    • (2011) N Engl J Med , vol.364 , pp. 1207-1217
    • Bacon, B.R.1    Gordon, S.C.2    Lawitz, E.3
  • 27
    • 84905581562 scopus 로고    scopus 로고
    • Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C
    • Fujino H, Imamura M, Nagaoki Y, et al. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. J Gastroenterol 2013; DOI: 10.1007/s00535-013-0924-9.
    • (2013) J Gastroenterol
    • Fujino, H.1    Imamura, M.2    Nagaoki, Y.3
  • 28
    • 84880277735 scopus 로고    scopus 로고
    • Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C
    • Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 2013; 59: 205-12.
    • (2013) J Hepatol , vol.59 , pp. 205-212
    • Furusyo, N.1    Ogawa, E.2    Nakamuta, M.3
  • 29
    • 84902127142 scopus 로고    scopus 로고
    • Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
    • Colombo M, Fernandez I, Abdurakhmanov D, et al. Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut 2014a; 63: 1150-8.
    • (2014) Gut , vol.63 , pp. 1150-1158
    • Colombo, M.1    Fernandez, I.2    Abdurakhmanov, D.3
  • 30
    • 84932190976 scopus 로고    scopus 로고
    • Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: the international telaprevir access program
    • Colombo M, Strasser S, Moreno C, et al. Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: the international telaprevir access program. J Hepatol 2014b; 61: 976-83.
    • (2014) J Hepatol , vol.61 , pp. 976-983
    • Colombo, M.1    Strasser, S.2    Moreno, C.3
  • 31
    • 84882908504 scopus 로고    scopus 로고
    • Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
    • Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59: 434-41.
    • (2013) J Hepatol , vol.59 , pp. 434-441
    • Hezode, C.1    Fontaine, H.2    Dorival, C.3
  • 32
    • 84902953427 scopus 로고    scopus 로고
    • Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis
    • e4.
    • Hézode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-42, e4.
    • (2014) Gastroenterology , vol.147 , pp. 132-142
    • Hézode, C.1    Fontaine, H.2    Dorival, C.3
  • 33
    • 84926515857 scopus 로고    scopus 로고
    • Undetectable HCV-RNA at treatment week 8 resulted in high-sustained virologic response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program
    • Oct 14.
    • Bruno S, Bollani S, Zignego AL, et al. Undetectable HCV-RNA at treatment week 8 resulted in high-sustained virologic response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. J Viral Hepat 2014; Oct 14. doi:10.1111/jvh.12342.
    • (2014) J Viral Hepat
    • Bruno, S.1    Bollani, S.2    Zignego, A.L.3
  • 34
    • 84906053496 scopus 로고    scopus 로고
    • Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
    • Jacobson I, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-13.
    • (2014) Lancet , vol.384 , pp. 403-413
    • Jacobson, I.1    Dore, G.J.2    Foster, G.R.3
  • 35
    • 84906059095 scopus 로고    scopus 로고
    • Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
    • Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-26.
    • (2014) Lancet , vol.384 , pp. 414-426
    • Manns, M.1    Marcellin, P.2    Poordad, F.3
  • 36
    • 84904723744 scopus 로고    scopus 로고
    • Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial
    • Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014; 61: 219-27.
    • (2014) J Hepatol , vol.61 , pp. 219-227
    • Hayashi, N.1    Izumi, N.2    Kumada, H.3
  • 37
    • 84901217985 scopus 로고    scopus 로고
    • Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial
    • e3.
    • Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-79, e3.
    • (2014) Gastroenterology , vol.146 , pp. 1669-1679
    • Forns, X.1    Lawitz, E.2    Zeuzem, S.3
  • 38
    • 84877730954 scopus 로고    scopus 로고
    • Sofosbuvir for previously untreated chronic hepatitis C infection
    • Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
    • (2013) N Engl J Med , vol.368 , pp. 1878-1887
    • Lawitz, E.1    Mangia, A.2    Wyles, D.3
  • 39
    • 84877739274 scopus 로고    scopus 로고
    • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
    • Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
    • (2013) N Engl J Med , vol.368 , pp. 1867-1877
    • Jacobson, I.M.1    Gordon, S.C.2    Kowdley, K.V.3
  • 40
    • 84919699728 scopus 로고    scopus 로고
    • Virologic response rates to Sofosbuvir-containing regimens are similar in patients with and without traditional negative predictive factors: a retrospective analysis of phase 3 data [abstract 1115]
    • Mangia A, Kugelmas M, Everson G, et al. Virologic response rates to Sofosbuvir-containing regimens are similar in patients with and without traditional negative predictive factors: a retrospective analysis of phase 3 data [abstract 1115]. Annual Meeting of the American Association for the Study of Liver Diseases, 2013.
    • (2013) Annual Meeting of the American Association for the Study of Liver Diseases
    • Mangia, A.1    Kugelmas, M.2    Everson, G.3
  • 41
    • 84899068302 scopus 로고    scopus 로고
    • Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
    • Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-603.
    • (2014) N Engl J Med , vol.370 , pp. 1594-1603
    • Feld, J.J.1    Kowdley, K.V.2    Coakley, E.3
  • 42
    • 84901044326 scopus 로고    scopus 로고
    • ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
    • Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-92.
    • (2014) N Engl J Med , vol.370 , pp. 1983-1992
    • Ferenci, P.1    Bernstein, D.2    Lalezari, J.3
  • 43
    • 84901036125 scopus 로고    scopus 로고
    • ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
    • Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-82.
    • (2014) N Engl J Med , vol.370 , pp. 1973-1982
    • Poordad, F.1    Hezode, C.2    Trinh, R.3
  • 44
    • 84899106124 scopus 로고    scopus 로고
    • Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
    • Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-14.
    • (2014) N Engl J Med , vol.370 , pp. 1604-1614
    • Zeuzem, S.1    Jacobson, I.M.2    Baykal, T.3
  • 45
    • 84906814530 scopus 로고    scopus 로고
    • All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
    • Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; doi: 10.1016/S0140-6736(14)61059-X.
    • (2014) Lancet
    • Manns, M.1    Pol, S.2    Jacobson, I.M.3
  • 46
    • 84890869379 scopus 로고    scopus 로고
    • HCV direct-acting antiviral agents: the best interferon-free combinations
    • Schinazi R, Halfon P, Marcellin P, et al. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014; 34(Suppl. 1): 69-78.
    • (2014) Liver Int , vol.34 , pp. 69-78
    • Schinazi, R.1    Halfon, P.2    Marcellin, P.3
  • 47
    • 84867737234 scopus 로고    scopus 로고
    • The hepatitis C virus infection as a systemic disease
    • Zignego AL, Gragnani L, Giannini C, et al. The hepatitis C virus infection as a systemic disease. Intern Emerg Med 2012; 7(Suppl. 3): S201-8.
    • (2012) Intern Emerg Med , vol.7 , pp. S201-S208
    • Zignego, A.L.1    Gragnani, L.2    Giannini, C.3
  • 48
    • 33745572348 scopus 로고    scopus 로고
    • Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C
    • Saadoun D, Asselah T, Resche-Rigon M, et al. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. Hepatology 2006; 43: 1337-45.
    • (2006) Hepatology , vol.43 , pp. 1337-1345
    • Saadoun, D.1    Asselah, T.2    Resche-Rigon, M.3
  • 49
    • 84918840101 scopus 로고    scopus 로고
    • Peg-IFNαRibavirin/Protease inhibitor combination in severe hepatitis C virus associated mixed cryoglobulinemia vasculitis
    • Saadoun D, Resche RM, Pol S, et al. Peg-IFNαRibavirin/Protease inhibitor combination in severe hepatitis C virus associated mixed cryoglobulinemia vasculitis. J Hepatol 2014; doi: 10.1016/j.jhep.2014.08.015.
    • (2014) J Hepatol
    • Saadoun, D.1    Resche, R.M.2    Pol, S.3
  • 50
    • 84906309287 scopus 로고    scopus 로고
    • Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study
    • Gragnani L, Fabrizzi A, Triboli E, et al. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study. Dig Liver Dis 2014; 46: 833-7.
    • (2014) Dig Liver Dis , vol.46 , pp. 833-837
    • Gragnani, L.1    Fabrizzi, A.2    Triboli, E.3
  • 51
    • 84925229519 scopus 로고    scopus 로고
    • Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir
    • Stine JG, Cornella S, Shah NL. Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir. Ann Rheum Dis 2014; 73: e64.
    • (2014) Ann Rheum Dis , vol.73 , pp. e64
    • Stine, J.G.1    Cornella, S.2    Shah, N.L.3
  • 52
    • 63349097919 scopus 로고    scopus 로고
    • Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C
    • Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49: 739-44.
    • (2009) Hepatology , vol.49 , pp. 739-744
    • Arase, Y.1    Suzuki, F.2    Suzuki, Y.3
  • 53
    • 77953482821 scopus 로고    scopus 로고
    • In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C
    • Asselah T, Bièche I, Mansouri A, et al. In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C. J Pathol 2010; 221: 264-74.
    • (2010) J Pathol , vol.221 , pp. 264-274
    • Asselah, T.1    Bièche, I.2    Mansouri, A.3
  • 54
    • 43549124805 scopus 로고    scopus 로고
    • Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection
    • Petta S, Cammà C, Di Marco V, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008; 103: 1136-44.
    • (2008) Am J Gastroenterol , vol.103 , pp. 1136-1144
    • Petta, S.1    Cammà, C.2    Di Marco, V.3
  • 55
    • 77952630118 scopus 로고    scopus 로고
    • Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection
    • Hung CH, Wang JH, Hu TH, et al. Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol 2010; 16: 2265-71.
    • (2010) World J Gastroenterol , vol.16 , pp. 2265-2271
    • Hung, C.H.1    Wang, J.H.2    Hu, T.H.3
  • 56
    • 84896492970 scopus 로고    scopus 로고
    • Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients
    • Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59: 1293-302.
    • (2014) Hepatology , vol.59 , pp. 1293-1302
    • Hsu, Y.C.1    Lin, J.T.2    Ho, H.J.3
  • 57
    • 84887531199 scopus 로고    scopus 로고
    • Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?
    • Grasso A, Malfatti F, Testa R. Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C? World J Gastroenterol 2013; 19: 6947-56.
    • (2013) World J Gastroenterol , vol.19 , pp. 6947-6956
    • Grasso, A.1    Malfatti, F.2    Testa, R.3
  • 58
    • 0141674800 scopus 로고    scopus 로고
    • Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis
    • Gisbert JP, García-Buey L, Pajares JM, et al. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 2003; 39: 620-7.
    • (2003) J Hepatol , vol.39 , pp. 620-627
    • Gisbert, J.P.1    García-Buey, L.2    Pajares, J.M.3
  • 59
    • 0028969640 scopus 로고
    • Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda
    • Takikawa H, Yamazaki R, Shoji S, et al. Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol 1995; 22: 249-50.
    • (1995) J Hepatol , vol.22 , pp. 249-250
    • Takikawa, H.1    Yamazaki, R.2    Shoji, S.3
  • 60
    • 0028876341 scopus 로고
    • Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations
    • Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123: 615-20.
    • (1995) Ann Intern Med , vol.123 , pp. 615-620
    • Gumber, S.C.1    Chopra, S.2
  • 61
    • 68949183159 scopus 로고    scopus 로고
    • Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus
    • Berenguer J, Alvarez-Pellicer J, Martín PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-13.
    • (2009) Hepatology , vol.50 , pp. 407-413
    • Berenguer, J.1    Alvarez-Pellicer, J.2    Martín, P.M.3
  • 63
    • 28844509556 scopus 로고    scopus 로고
    • Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy
    • Bräu N, Salvatore M, Ríos-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55.
    • (2006) J Hepatol , vol.44 , pp. 47-55
    • Bräu, N.1    Salvatore, M.2    Ríos-Bedoya, C.F.3
  • 64
    • 84861821680 scopus 로고    scopus 로고
    • Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection
    • Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18: 716-26.
    • (2012) Liver Transpl , vol.18 , pp. 716-726
    • Terrault, N.A.1    Roland, M.E.2    Schiano, T.3
  • 65
    • 84942328942 scopus 로고    scopus 로고
    • Response-guided Boceprevir-based triple-therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study
    • pii: jiu516
    • Mandorfer M, Steiner S, Schwabl P, et al. Response-guided Boceprevir-based triple-therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study. J Infect Dis 2014; pii: jiu516.
    • (2014) J Infect Dis
    • Mandorfer, M.1    Steiner, S.2    Schwabl, P.3
  • 66
    • 84891835213 scopus 로고    scopus 로고
    • Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection
    • Martel-Laferrière V, Brinkley S, Bichoupan K, et al. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med 2014; 15: 108-15.
    • (2014) HIV Med , vol.15 , pp. 108-115
    • Martel-Laferrière, V.1    Brinkley, S.2    Bichoupan, K.3
  • 67
    • 84906851923 scopus 로고    scopus 로고
    • CROI 2014: viral hepatitis and complications of HIV disease and antiretroviral therapy
    • Luetkemeyer AF, Havlir DV, Currier JS. CROI 2014: viral hepatitis and complications of HIV disease and antiretroviral therapy. Top Antivir Med 2014; 22: 602-15.
    • (2014) Top Antivir Med , vol.22 , pp. 602-615
    • Luetkemeyer, A.F.1    Havlir, D.V.2    Currier, J.S.3
  • 68
    • 84902292538 scopus 로고    scopus 로고
    • Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection
    • Sagnelli E, Pisaturo M, Martini S, et al. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. Expert Opin Pharmacother 2014; 15: 1337-49.
    • (2014) Expert Opin Pharmacother , vol.15 , pp. 1337-1349
    • Sagnelli, E.1    Pisaturo, M.2    Martini, S.3
  • 69
    • 84984585800 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
    • e3.
    • Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009; 136: 496-504, e3.
    • (2009) Gastroenterology , vol.136 , pp. 496-504
    • Liu, C.J.1    Chuang, W.L.2    Lee, C.M.3
  • 70
    • 84984578350 scopus 로고    scopus 로고
    • Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
    • Yu ML, Lee CM, Chen CL, et al. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology 2013; 57: 2135-42.
    • (2013) Hepatology , vol.57 , pp. 2135-2142
    • Yu, M.L.1    Lee, C.M.2    Chen, C.L.3
  • 71
    • 84893500217 scopus 로고    scopus 로고
    • Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality
    • Liu CJ, Chu YT, Shau WY, et al. Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut 2014; 63: 506-14.
    • (2014) Gut , vol.63 , pp. 506-514
    • Liu, C.J.1    Chu, Y.T.2    Shau, W.Y.3
  • 72
    • 84899651307 scopus 로고    scopus 로고
    • Peg-interferon Plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors
    • Coppola N, Pisaturo M, Sagnelli C, et al. Peg-interferon Plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PLoS ONE 2014; 9: e94542.
    • (2014) PLoS ONE , vol.9 , pp. e94542
    • Coppola, N.1    Pisaturo, M.2    Sagnelli, C.3
  • 73
    • 72449191348 scopus 로고    scopus 로고
    • Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin
    • Potthoff A, Berg T, Wedemeyer H, et al. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol 2009; 44: 1487-90.
    • (2009) Scand J Gastroenterol , vol.44 , pp. 1487-1490
    • Potthoff, A.1    Berg, T.2    Wedemeyer, H.3
  • 74
    • 78650307256 scopus 로고    scopus 로고
    • Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand
    • Scott DR, Wong JK, Spicer TS, et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation 2010; 90: 1165-71.
    • (2010) Transplantation , vol.90 , pp. 1165-1171
    • Scott, D.R.1    Wong, J.K.2    Spicer, T.S.3
  • 75
    • 70349733011 scopus 로고    scopus 로고
    • Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation
    • Van Wagner LB, Baker T, Ahya SN, et al. Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. J Hepatol 2009; 51: 874-80.
    • (2009) J Hepatol , vol.51 , pp. 874-880
    • Van Wagner, L.B.1    Baker, T.2    Ahya, S.N.3
  • 76
    • 84893768533 scopus 로고    scopus 로고
    • Cardiovascular disease and HCV infection: a simple association or more?
    • Petta S, Macaluso FS, Craxì A. Cardiovascular disease and HCV infection: a simple association or more? Gut 2014; 63: 369-75.
    • (2014) Gut , vol.63 , pp. 369-375
    • Petta, S.1    Macaluso, F.S.2    Craxì, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.